ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.